![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The financing will enable the company to progress in the development of lead compound ISM-001, which is a high affinity, neutralising antibody that specifically binds VEGF165b for the treatment of peripheral arterial disease.
Lead Product(s): ISM-001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ISM-001
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Broadview Ventures
Deal Size: $9.4 million Upfront Cash: Undisclosed
Deal Type: Financing February 20, 2024